Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 15(8): e0236333, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32776943

RESUMO

Research on the songbird zebra finch (Taeniopygia guttata) has advanced our behavioral, hormonal, neuronal, and genetic understanding of vocal learning. However, little is known about the impact of typical experimental manipulations on the welfare of these birds. Here we explore whether the undirected singing rate can be used as an indicator of welfare. We tested this idea by performing a post hoc analysis of singing behavior in isolated male zebra finches subjected to interactive white noise, to surgery, or to tethering. We find that the latter two experimental manipulations transiently but reliably decreased singing rates. By contraposition, we infer that a high-sustained singing rate is suggestive of successful coping or improved welfare in these experiments. Our analysis across more than 300 days of song data suggests that a singing rate above a threshold of several hundred song motifs per day implies an absence of an acute stressor or a successful coping with stress. Because singing rate can be measured in a completely automatic fashion, its observation can help to reduce experimenter bias in welfare monitoring. Because singing rate measurements are non-invasive, we expect this study to contribute to the refinement of the current welfare monitoring tools in zebra finches.


Assuntos
Adaptação Psicológica/fisiologia , Bem-Estar do Animal , Monitorização de Parâmetros Ecológicos/métodos , Tentilhões/fisiologia , Vocalização Animal/fisiologia , Acústica , Animais , Masculino , Isolamento Social
2.
Pulm Pharmacol Ther ; 45: 90-94, 2017 08.
Artigo em Inglês | MEDLINE | ID: mdl-28499635

RESUMO

Chronic inflammatory lung diseases remain a health concern and new anti-inflammatory treatments are needed. Targeting adenosine A2A receptors (A2AR) affords robust anti-inflammatory effects in animal models, but the translation of this promising strategy to humans has been challenging, possibly due to interspecies differences in receptor distribution and effects. Thus, we now assessed the efficiency of a selective A2AR agonist to control the activation of fresh human alveolar inflammatory cells. We collected bronchoalveolar lavage fluid from patients with interstitial lung disease and loaded alveolar cells with the intracellular free calcium probe FURA-2/AM. Calcium transients were then recorded in response to superfusion with a proinflammatory peptide (N-formylmethionyl-leucyl-phenylalanine - FMLP), in the absence or presence of the selective A2AR agonist CGS21680. In a second experiment, cells were continuously exposed to FMLP and A2AR density was assessed by immunocytochemistry. Sixteen patients were included, nine for analysis of calcium transients, and seven for immunocytochemistry. When alveolar macrophages were exposed to 100 nM FMLP for 120 s, a peak elevation of intracellular free calcium levels (97.0% over baseline) was recorded; CGS21680 (100 and 300 mM) significantly reduced this peak to 89.5% and 81.5%, respectively. The immunofluorescence analysis revealed a time-dependent increase of A2AR density in alveolar macrophage upon exposure to 1 µM FMLP, up to 148% of control at 6 h. These results show that pro-inflammatory stimuli up-regulate A2AR and their activation dampens the impact of pro-inflammatory stimuli. This supports that targeting A2AR is a promising therapy for human lung inflammatory diseases, especially for diseases with a strong inflammatory component.


Assuntos
Adenosina/análogos & derivados , Doenças Pulmonares Intersticiais/tratamento farmacológico , Macrófagos Alveolares/metabolismo , Fenetilaminas/farmacologia , Receptor A2A de Adenosina/efeitos dos fármacos , Adenosina/administração & dosagem , Adenosina/farmacologia , Agonistas do Receptor A2 de Adenosina/administração & dosagem , Agonistas do Receptor A2 de Adenosina/farmacologia , Adulto , Cálcio/metabolismo , Relação Dose-Resposta a Droga , Feminino , Imunofluorescência , Corantes Fluorescentes , Fura-2 , Humanos , Doenças Pulmonares Intersticiais/patologia , Masculino , Pessoa de Meia-Idade , N-Formilmetionina Leucil-Fenilalanina/administração & dosagem , Fenetilaminas/administração & dosagem , Estudos Prospectivos , Receptor A2A de Adenosina/genética , Fatores de Tempo , Regulação para Cima
3.
Mol Neurobiol ; 54(2): 1552-1563, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-26860412

RESUMO

Caffeine prophylactically prevents mood and memory impairments through adenosine A2A receptor (A2AR) antagonism. A2AR antagonists also therapeutically revert mood and memory impairments, but it is not known if caffeine is also therapeutically or only prophylactically effective. Since depression is accompanied by mood and memory alterations, we now explored if chronic (4 weeks) caffeine consumption (0.3 g/L) reverts mood and memory impairment in helpless mice (HM, 12 weeks old), a bred-based model of depression. HM displayed higher immobility in the tail suspension and forced swimming tests, greater anxiety in the elevated plus maze, and poorer memory performance (modified Y-maze and object recognition). HM also had reduced density of synaptic (synaptophysin, SNAP-25), namely, glutamatergic (vGluT1; -22 ± 7 %) and GABAergic (vGAT; -23 ± 8 %) markers in the hippocampus. HM displayed higher A2AR density (72 ± 6 %) in hippocampal synapses, an enhanced facilitation of hippocampal glutamate release by the A2AR agonist, CGS21680 (30 nM), and a larger LTP amplitude (54 ± 8 % vs. 21 ± 5 % in controls) that was restored to control levels (30 ± 10 %) by the A2AR antagonist, SCH58261 (50 nM). Notably, caffeine intake reverted memory deficits and reverted the loss of hippocampal synaptic markers but did not affect helpless or anxiety behavior. These results reinforce the validity of HM as an animal model of depression by showing that they also display reference memory deficits. Furthermore, caffeine intake selectively reverted memory but not mood deficits displayed by HM, which are associated with an increased density and functional impact of hippocampal A2AR controlling synaptic glutamatergic function.


Assuntos
Cafeína/uso terapêutico , Depressão/metabolismo , Ácido Glutâmico/metabolismo , Transtornos da Memória/metabolismo , Transtornos do Humor/metabolismo , Receptor A2A de Adenosina/biossíntese , Animais , Cafeína/farmacologia , Estimulantes do Sistema Nervoso Central/farmacologia , Estimulantes do Sistema Nervoso Central/uso terapêutico , Depressão/tratamento farmacológico , Depressão/psicologia , Relação Dose-Resposta a Droga , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Masculino , Transtornos da Memória/tratamento farmacológico , Transtornos da Memória/psicologia , Camundongos , Transtornos do Humor/tratamento farmacológico , Transtornos do Humor/psicologia , Especificidade da Espécie , Sinapses/efeitos dos fármacos , Sinapses/metabolismo , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologia
4.
Eur J Neurosci ; 40(3): 2479-86, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24766164

RESUMO

Cellular prion protein (PrP(C) ) is widely expressed in the brain. Although the precise role of PrP(C) remains uncertain, it has been proposed to be a pivotal modulator of neuroplasticity events by regulating the glutamatergic and serotonergic systems. Here we report the existence of neurochemical and functional interactions between PrP(C) and the dopaminergic system. PrP(C) was found to co-localize with dopaminergic neurons and in dopaminergic synapses in the striatum. Furthermore, the genetic deletion of PrP(C) down-regulated dopamine D1 receptors and DARPP-32 density in the striatum and decreased dopamine levels in the prefrontal cortex of mice. This indicates that PrP(C) affects the homeostasis of the dopaminergic system by interfering differently in different brain areas with dopamine synthesis, content, receptor density and signaling pathways. This interaction between PrP(C) and the dopaminergic system prompts the hypotheses that the dopaminergic system may be implicated in some pathological features of prion-related diseases and, conversely, that PrP(C) may play a role in dopamine-associated brain disorders.


Assuntos
Dopamina/biossíntese , Neurônios Dopaminérgicos/metabolismo , Neostriado/metabolismo , Proteínas PrPC/metabolismo , Animais , Fosfoproteína 32 Regulada por cAMP e Dopamina/análise , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Atividade Motora/fisiologia , Proteínas PrPC/genética , Córtex Pré-Frontal/metabolismo , Receptores de Dopamina D1/metabolismo
5.
J Alzheimers Dis ; 40(4): 981-92, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24531160

RESUMO

Amyloid-ß protein precursor (AßPP) is a large transmembrane protein highly expressed in the central nervous system and cleavage of it can produce amyloid-ß peptides (Aß) involved in synaptic dysfunction and loss associated with cognitive impairment in Alzheimer's disease (AD). Surprisingly, little is known about the synaptic and sub-synaptic distribution of AßPP in different types of nerve terminals. We used total, synaptic, sub-synaptic, and astrocytic membrane preparations obtained from the hippocampus of adult rats to define the localization of AßPP, using two different antibodies against different AßPP epitopes. Western blot analysis revealed that AßPP was not significantly enriched in synaptosomal as compared to total membranes. Within synapses, AßPP immunoreactivity was more abundant in pre- (60 ± 4%) than post- (30 ± 5%) or extra-synaptic fractions (10 ± 2%). Immunocytochemical analysis of purified nerve terminals indicated that AßPP was more frequently associated with glutamatergic (present in 31 ± 4% of glutamatergic terminals) rather than with GABAergic (16 ± 3%) or cholinergic terminals (4 ± 1%, n = 4). We also observed a general lack of co-localization of AßPP and GFAP immunoreactivities in the hippocampus of sections of adult rat brain, albeit we could detect the presence of AßPP in gliosomes (vesicular specializations of astrocytic membranes), suggesting that AßPP has a heterogeneous localization restricted to certain regions of astrocytes. These results provide the first direct demonstration that AßPP is mostly distributed among glutamatergic rather than GABAergic or cholinergic terminals of the adult rat hippocampus, in remarkable agreement with the particular susceptibility to dysfunction and degeneration of glutamatergic synapses in early AD.


Assuntos
Precursor de Proteína beta-Amiloide/metabolismo , Hipocampo/ultraestrutura , Sinapses/metabolismo , Sinaptossomos/metabolismo , Análise de Variância , Animais , Astrócitos/metabolismo , Astrócitos/ultraestrutura , Membrana Celular/metabolismo , Membrana Celular/ultraestrutura , Transportador de Glucose Tipo 1/metabolismo , Masculino , Ratos , Ratos Wistar , Sinapses/ultraestrutura , Sinaptossomos/diagnóstico por imagem , Ultrassonografia , Proteínas Vesiculares de Transporte de Acetilcolina/metabolismo , Proteínas Vesiculares de Transporte de Aminoácidos Inibidores/metabolismo
6.
J Neuroinflammation ; 10: 16, 2013 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-23363775

RESUMO

BACKGROUND: Brain-derived neurotrophic factor (BDNF) has been shown to control microglial responses in neuropathic pain. Since adenosine A2A receptors (A2ARs) control neuroinflammation, as well as the production and function of BDNF, we tested to see if A2AR controls the microglia-dependent secretion of BDNF and the proliferation of microglial cells, a crucial event in neuroinflammation. METHODS: Murine N9 microglial cells were challenged with lipopolysaccharide (LPS, 100 ng/mL) in the absence or in the presence of the A2AR antagonist, SCH58261 (50 nM), as well as other modulators of A2AR signaling. The BDNF cellular content and secretion were quantified by Western blotting and ELISA, A2AR density was probed by Western blotting and immunocytochemistry and cell proliferation was assessed by BrdU incorporation. Additionally, the A2AR modulation of LPS-driven cell proliferation was also tested in primary cultures of mouse microglia. RESULTS: LPS induced time-dependent changes of the intra- and extracellular levels of BDNF and increased microglial proliferation. The maximal LPS-induced BDNF release was time-coincident with an LPS-induced increase of the A2AR density. Notably, removing endogenous extracellular adenosine or blocking A2AR prevented the LPS-mediated increase of both BDNF secretion and proliferation, as well as exogenous BDNF-induced proliferation. CONCLUSIONS: We conclude that A2AR activation plays a mandatory role controlling the release of BDNF from activated microglia, as well as the autocrine/paracrine proliferative role of BDNF.


Assuntos
Antagonistas do Receptor A2 de Adenosina/farmacologia , Fator Neurotrófico Derivado do Encéfalo/antagonistas & inibidores , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Proliferação de Células , Microglia/metabolismo , Receptor A2A de Adenosina/fisiologia , Animais , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Lipopolissacarídeos/farmacologia , Camundongos , Camundongos Endogâmicos C57BL
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...